Skip to main content
PMC home page
Nature Portfolio logoLink to Nature Portfolio
. 2023 Oct 9;29(10):2665. doi: 10.1038/s41591-023-02624-w

Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial

Roch Houot 1,✉, Emmanuel Bachy 2, Guillaume Cartron 3, François-Xavier Gros 4, Franck Morschhauser 5, Lucie Oberic 6, Thomas Gastinne 7, Pierre Feugier 8, Rémy Duléry 9, Catherine Thieblemont 10, Magalie Joris 11, Fabrice Jardin 12, Sylvain Choquet 13, Olivier Casasnovas 14, Gabriel Brisou 15, Morgane Cheminant 16, Jacques-Olivier Bay 17, Francisco Llamas Gutierrez 18, Cédric Menard 19, Karin Tarte 19, Marie-Hélène Delfau 20, Cédric Portugues 21, Emmanuel Itti 22, Xavier Palard-Novello 23, Paul Blanc-Durand 24, Yassine Al Tabaa 25, Clément Bailly 26, Camille Laurent 27, François Lemonnier 28
PMCID: PMC10579050  PMID: 37814064

Correction to: Nature Medicine 10.1038/s41591-023-02572-5, published online 14 September 2023.

In the version of this article initially published, the title of the paper, now reading “Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial,” appeared incorrectly as “Axicabtagene ciloleucel in large B cell lymphoma ineligible for autologous stem cell transplantation: the phase 2 ALYCANTE trial.” The title has been updated in the HTML and PDF versions of the article.

Articles from Nature Medicine are provided here courtesy of Nature Publishing Group

RESOURCES